
    
      The study will be conducted at the UW Primary Infection Clinic and the UW AIDS Clinical
      Trials Unit. Secondary objectives will characterize safety, tolerability, plasma HIV-1 RNA
      and CD4+ T-cell values. The 3-drug HAART will be chosen and provided by the subject.
    
  